Floxium (levofloxacin) solution for infusions 5 mg/ml. 100 ml. №1 vial


Manufacturer: Ukraine

Floxium is indicated for the treatment of adult infections caused by levofloxacin-sensitive microorganisms: acute bacterial sinusitis; exacerbation of chronic bronchitis; community-acquired pneumonia; complicated skin and soft tissue infections. In the case of treatment of the above-mentioned infections, the drug is used only when the use of other antibacterial agents, which are usually prescribed for the initial treatment of these infections, is impossible. complicated urinary tract infections (including pyelonephritis); chronic bacterial prostatitis; uncomplicated cystitis; pulmonary form of anthrax: post-contact prevention and treatment. Floxium in this dosage form (tablets) can be used to complete a course of therapy for patients who have demonstrated improvement during primary treatment with Floxium, an injectable solution. Official recommendations for the proper use of antibacterial agents should be taken into account.



Floxium №1 vial Composition
active substance: levofloxacin;

100 ml of solution contain levofloxacin hemihydrate – 512.46 mg, in terms of lefoloxacin – 500.0 mg;

excipients: sodium chloride; sodium hydroxide; concentrated hydrochloric acid; water for injections.

Floxium №1 vial Dosage form
Solution for infusion.

Basic physical and chemical properties: clear solution from yellow to greenish-yellow color.

Floxium №1 vial Pharmacotherapeutic group
Antibacterial agents of the quinolone group. Fluoroquinolones. ATX code J01M A12.

Levofloxacin is a synthetic antibacterial drug from the group of fluoroquinolones, the S-enantiomer of the racemic mixture of the drug ofloxacin.

Mechanism of action.

As an antibacterial drug from the group of fluoroquinolones, levofloxacin acts on the DNA-DNA gyrase and topoisomerase IV complex.

Pharmacokinetics / pharmacodynamics ratio. The degree of bacterial activity of levofloxacin depends on the ratio of the maximum serum concentration (Cmax) or the area under the pharmacokinetic curve (AUC) and the minimum inhibitory concentration (MIC).

Mechanism of resistance

Resistance to levofloxacin is acquired as a stepwise process of target site mutation in both types of topoisomerase II, DNA gyrase and topoisomerase IV. Other mechanisms of resistance, such as barrier penetration (common with Pseudomonas) and efflux mechanisms, can also influence sensitivity to levofloxacin.

Cross-resistance has been established between levofloxacin and other fluoroquinolones.

Due to its mechanism of action, there is usually no cross-resistance between levofloxacin and other classes of antibacterial drugs.

Floxium, solution for infusion is intended for the treatment of the following infectious diseases in adults

Community-acquired pneumonia.
Complicated infections of the skin and soft tissues.
Regarding the above infectious diseases, levofloxacin should be prescribed only in cases of insufficient efficacy of other antibacterial drugs, which are mainly used for the initial treatment of these infections.

Pyelonephritis and complicated urinary tract infections.
Chronic bacterial prostatitis.
Pulmonary anthrax: post-exposure prophylaxis and radical treatment.
Floxium, solution for infusion, do not prescribe in the following cases:

hypersensitivity to the active pharmaceutical ingredient or other quinolones or to any other components of the drug;
disorders of the tendons after the use of fluoroquinolones;
children and adolescents;
lactation period.